Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended

2023-509408-13-00 Solid tumors 6 2022-09-20
SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for… Ended

2024-514569-20-00 muscle-invasive bladder cancer 4 2022-09-15
A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t… Ended

2024-511917-40-00 Advanced Upper Gastrointestinal Tract Malignancies 4 2022-09-13
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended

2023-504194-21-00 PD-L1 Positive Metastatic Triple-Negative Breast Cancer 5 2022-09-13
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended

2023-504187-42-00 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leuk 1 2022-09-12
Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended

2023-505302-42-00 BRAF(V600) mutation-positive melanoma with brain metast 4 2022-09-05
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Ended

2024-512120-11-00 Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast 7 2022-08-31
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or… Ended

2024-512045-16-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 5 2022-08-18
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom… Ended

2022-501380-40-00 Diffuse large B-cell lymphoma (DLBCL) 4 2022-08-10
Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended

2024-516604-41-00 Non-small Cell Lung Cancer 4 2022-08-08
Lorlatinib Continuation Study Ended

2023-508952-21-00 Lung cancer 6 2022-08-02
First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cance… Ended

2024-511021-58-00 Extensive Stage Small cell lung cancer (ES-SCLC) 3 2022-08-02
A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended

2024-513611-28-00 Metastatic Solid Tumors 4 2022-07-29
A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP… Ended

2023-506582-58-00 Acute Myeloid Leukemia 3 2022-07-21
A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance… Ended

2023-504996-26-00 Metastatic Castration Resistant Prostate Cancer (mCRPC) 5 2022-07-21
A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended

2024-514891-41-00 HR+, HER2- advanced or metastatic breast cancer 6 2022-07-19
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone o… Ended

2023-507019-36-00 Relapsed or Refractory Multiple Myeloma (R/R MM) 3 2022-07-08
A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic U… Ended

2024-514657-30-00 Metastatic uveal melanoma 4 2022-07-07
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24